Brandenburg Kapital - News about SphingoTec GmbH
Strong alliance for better patient care: Boditech and SphingoTec launch penKid® assay for assessing kidney function
Hennigsdorf – May 2025. Boditech Med Inc. and SphingoTec announce the launch of the AFIAS sphingotest® penKid® assay, a new diagnostic test designed to improve the assessment of kidney function in critically ill patients.
The IVDR-compliant test enables quantitative measurements of the penKid biomarker in patients' blood, thereby supporting clinical decision-making in acute and intensive care. penKid (proenkephalin A 119-159), Sphingotec's patented biomarker, enables early assessment of kidney function.
This launch is the result of a strategic collaboration between Boditech and SphingoTec, which aims to provide clinicians worldwide with innovative diagnostic solutions for the treatment of critically ill patients.
SphingoTec develops and markets innovative in vitro diagnostic solutions for novel biomarkers for intensive care medicine. The biomarkers provide important, organ-specific information for monitoring acute disease progression, such as sepsis or acute kidney failure. In this way, they support clinical decisions with the aim of improving both patient care and management.
Brandenburg Kapital GmbH has been supporting the company since 2018.
Read the full press release here:
Further information can be found at: www.brandenburg-kapital.de, www.sphingotec.com